Wells Fargo’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.34M Buy
147,135
+26,354
+22% +$572K ﹤0.01% 3154
2025
Q4
$3.17M Buy
120,781
+87,329
+261% +$2.27M ﹤0.01% 3069
2025
Q3
$756K Sell
33,452
-14,028
-30% -$289K ﹤0.01% 4005
2025
Q2
$944K Sell
47,480
-30,053
-39% -$586K ﹤0.01% 3724
2025
Q1
$1.31M Buy
77,533
+63,523
+453% +$1.08M ﹤0.01% 3480
2024
Q4
$259K Buy
14,010
+2,489
+22% +$48.6K ﹤0.01% 4640
2024
Q3
$250K Buy
11,521
+630
+6% +$14.1K ﹤0.01% 4430
2024
Q2
$214K Buy
10,891
+598
+6% +$12.5K ﹤0.01% 4478
2024
Q1
$223K Buy
10,293
+302
+3% +$7.5K ﹤0.01% 4404
2023
Q4
$289K Buy
9,991
+1,130
+13% +$30.2K ﹤0.01% 4239
2023
Q3
$237K Sell
8,861
-4,371
-33% -$149K ﹤0.01% 4251
2023
Q2
$490K Buy
13,232
+3,894
+42% +$136K ﹤0.01% 3957
2023
Q1
$292K Buy
9,338
+3,283
+54% +$106K ﹤0.01% 4203
2022
Q4
$180K Sell
6,055
-345
-5% -$12.3K ﹤0.01% 4227
2022
Q3
$244K Sell
6,400
-7,457
-54% -$374K ﹤0.01% 4125
2022
Q2
$755K Sell
13,857
-19,745
-59% -$1.09M ﹤0.01% 3475
2022
Q1
$2.1M Sell
33,602
-28,722
-46% -$1.89M ﹤0.01% 3247
2021
Q4
$6.27M Buy
62,324
+9,482
+18% +$833K ﹤0.01% 2340
2021
Q3
$4.75M Sell
52,842
-5,241
-9% -$476K ﹤0.01% 2874
2021
Q2
$5.36M Sell
58,083
-5,691
-9% -$454K ﹤0.01% 2807
2021
Q1
$6.16M Buy
63,774
+6,465
+11% +$667K ﹤0.01% 2646
2020
Q4
$2.98M Buy
57,309
+5,277
+10% +$221K ﹤0.01% 3195
2020
Q3
$2.08M Buy
52,032
+28,180
+118% +$882K ﹤0.01% 3278
2020
Q2
$382K Buy
23,852
+14,503
+155% +$222K ﹤0.01% 4511
2020
Q1
$100K Sell
9,349
-823
-8% -$11.5K ﹤0.01% 5054
2019
Q4
$131K Buy
+10,172
New +$121K ﹤0.01% 5176
2018
Q2
Sell
-500
Closed -$2K 6398
2018
Q1
$2K Hold
500
﹤0.01% 6192
2017
Q4
$2K Hold
500
﹤0.01% 6186
2017
Q3
$2K Hold
500
﹤0.01% 6148
2017
Q2
$3K Sell
500
-10,230
-95% -$82.5K ﹤0.01% 6001
2017
Q1
$118K Buy
10,730
+10,230
+2,046% +$121K ﹤0.01% 5125
2016
Q4
$6K Buy
+500
New +$4.72K ﹤0.01% 5913

Other funds holding FLGT

Wells Fargo's FLGT Position: Q1 2026 in Review

Wells Fargo increased its Fulgent Genetics (FLGT) stake by 22% in Q1 2026, buying an estimated $572K and bringing the position to 147,135 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Wells Fargo first reported a position in FLGT in Q4 2016 and has held it in 32 quarters since. The position peaked at $6.27M in Q4 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Wells Fargo held 147,135 shares of Fulgent Genetics worth $2.34M as of Q1 2026.
  • Wells Fargo bought 26,354 Fulgent Genetics shares in Q1 2026, an estimated $572K.
  • Fulgent Genetics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3154 holding.
  • Wells Fargo first reported a position in Fulgent Genetics in Q4 2016 and has held it in 32 quarters since.
  • Wells Fargo's Fulgent Genetics position peaked at $6.27M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.